Hummingbird Bioscience and Sanofi announce collaboration for the development of novel cancer therapeutics

0
1906

Hummingbird Bioscience (Read Biotechin.Asia’s feature here), an innovative biotechnology company focused on the discovery and early development of antibody therapeutics, today announced a collaboration with Sanofi, a global healthcare leader, to develop novel therapeutic antibodies for the treatment of cancer. The collaboration allows Sanofi access to Hummingbird’s proprietary Rational Antibody Development platform, a highly innovative approach to identifying functional antibodies for further development into therapeutics.

Screen Shot 2016-04-20 at 11.13.45 pm

Hummingbird Bioscience’s Rational Antibody Development platform is built on two technologies, mAbPredict and mAbHits that were developed by the founding team. By integrating structural, sequence and functional information, mAbPredict allows rapid identification and prioritization of the ideal target regions on a protein, while mAbHits facilitates rapid production of fully human antibodies against these regions. This technology enables Hummingbird to rapidly develop functional antibodies against most classes of proteins.

“We are delighted to work with the Hummingbird team to explore this highly innovative approach to developing therapeutic antibodies which potentially could significantly improve the time and cost of developing new biotherapeutics”, said Dr. Liang Schweizer, Head of Asian Cancer Research at Sanofi. “This agreement underscores the enormous promise of highly novel and systems biology driven approaches for drug discovery and development”.

Previous article[Event] 6th International Conference on Biotechnology for The Wellness Industry (ICBWI)
Next articleCapere Surgical Systems: Building a Global Orthopaedic Company in Singapore
Scientist-entrepreneur-manager-journalist: -Co-founder, Author; Former Assistant Editor and Director, Biotechin.Asia, Biotech Media Pte. Ltd.; -Founder & CEO, SciGlo (www.sciglo.com); -Programme Management Officer, SBIC, A*STAR (former Research Fellow). --Sandhya graduated from University of Madras, India (B.Sc Microbiology and M.Sc Biotechnology) and received her Ph.D from the Nanyang Technological University, Singapore. She worked on oxidative stress in skin, skeletal, adipose tissue and cardiac muscle for a decade from 2006-2016. She is currently working as a Programme Management Officer handling projects and grants at Singapore Bioimaging Consortium (SBIC), Agency for Science, Technology and Research (A*STAR). Earlier to this she was a Research Fellow in the Fat Metabolism and Stem Cell Group at SBIC. Sandhya was also the Vice President and Publicity Chair of A*PECSS (A*STAR Post Doc Society) (2014-2016). Recently she founded a platform for scientists - SciGlo (www.sciglo.com) and is a startup mentor at Vertical VC (Finland). She is an ardent lover of science and enjoys globe trotting and good vegetarian food.